XORTX Therapeutics has entered a $2,500,000 investor-relations agreement with IR Agency for Marketing and news distribution beginning September 3, 2026. The fee is fully earned when paid and cannot be refunded, while the consultant offers no guarantee that the program will increase XRTX trading Volume or price.
Key Highlights
- XORTX Therapeutics’ TSXV delisting received final approval on August 28, 2026, and took effect at the close of Business September 1, 2026.
- The prior IR arrangement ended August 7, 2026, with $2,500,000 returned to XORTX Therapeutics on August 14, 2026.
- IR Agency will not solicit securities orders, provide Investment advice or guarantee higher trading volume or price.
XORTX Therapeutics Inc. (NASDAQ: XRTX) has re-engaged IR Agency under a $2,500,000 investor-relations agreement covering marketing and news distribution. The program begins September 3, 2026, after the company completed its voluntary departure from the TSXV, while its common shares remain listed on the Nasdaq Capital Market.
$2.5M Marketing Agreement Terms
The revised arrangement followed the termination and rescission of an earlier agreement on August 7, 2026. Final TSXV approval arrived on August 28, 2026, and the delisting became effective at the close of business September 1, 2026. The new agreement provides marketing and Advertising services, including company profiles and distribution of company news, with the fee payable in advance by wire transfer. Either party can terminate the arrangement by written notice. The agreement can be extended by mutual consent, and XORTX Therapeutics reserved the returned funds for future investor-relations spending.
IR Agency's Responsibility for Market Response
IR Agency does not guarantee that the marketing program will increase XRTX trading volume or raise its trading price. The consultant also assumes no responsibility for the amount or duration of any potential increase. The agreement states that IR Agency assumes no responsibility for market response, trading volume, or price changes.
FAQs
Q: What is XORTX Therapeutics paying IR Agency?
A: XORTX Therapeutics agreed to pay IR Agency $2,500,000 in advance for marketing and news distribution services under the revised investor-relations agreement.
Q: When does XORTX Therapeutics’ IR agreement begin?
A: The revised IR agreement begins September 3, 2026, with a three-month term. It covers marketing and advertising services communicating company information to the financial community, including company profiles and media distribution of company news.
Q: Does IR Agency guarantee a higher XRTX stock price?
A: No. IR Agency assumes no responsibility for trading-volume or price changes and does not guarantee any increase in either measure.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.